Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Meiragtx Holdings ( (MGTX) ) is now available.
On April 20, 2026, MeiraGTx Holdings and affiliates completed the initial closing of a strategic collaboration with Guernsey-based Hologen Limited to jointly research, develop, manufacture and commercialize MeiraGTx’s AAV-GAD and AAV-BDNF gene therapy programs and its proprietary delivery device. The parties amended prior neuro and manufacturing framework agreements and entered a new collaboration and license pact, aligning ownership structures and funding mechanisms for these clinical programs and the device.
Ahead of closing, MeiraGTx Neuro UK and Hologen funded and structured shareholdings in Hologen Neuro AI Limited using a portion of a previously committed $200 million upfront payment, with Hologen ultimately set to own 70% and MeiraGTx 30% of HNAI after completion. In parallel, Hologen acquired and agreed to purchase additional minority stakes in MeiraGTx Manufacturing, with options that could raise Hologen’s ownership to up to 40% and a mirrored option later allowing MeiraGTx to buy back Hologen’s stake, shaping long-term control of key manufacturing assets.
The most recent analyst rating on (MGTX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Meiragtx Holdings stock, see the MGTX Stock Forecast page.
Spark’s Take on MGTX Stock
According to Spark, TipRanks’ AI Analyst, MGTX is a Neutral.
The score is primarily held back by weak financial performance—ongoing large losses, continued cash burn, and a weakened capital structure with negative equity. Offsetting this are constructive corporate developments (financing that extends runway and positive program/regulatory updates) and improving technical momentum with price above key moving averages.
To see Spark’s full report on MGTX stock, click here.
More about Meiragtx Holdings
MeiraGTx Holdings is a clinical-stage gene therapy company focused on developing genetic medicines targeting the central nervous system and other indications. Its primary programs include AAV-based investigational gene therapies and a proprietary delivery device designed for precise local administration of gene therapies into the brain, face, scalp and other tissues.
Average Trading Volume: 635,577
Technical Sentiment Signal: Buy
Current Market Cap: $862.6M
For a thorough assessment of MGTX stock, go to TipRanks’ Stock Analysis page.